ГИПЕРУРИКЕМИЯ, АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ И ХРОНИЧЕСКАЯ БОЛЕЗНЬ ПОЧЕК: ИНТЕРПРЕТАЦИЯ ВЗАИМОСВЯЗИ И СТРАТЕГИЯ ДЕЙСТВИЙ


Цитировать

Полный текст

Аннотация

Обсуждается значение гиперурикемии как фактора риска сердечно-сосудистых осложнений и хронической болезни почек и показания к ее лечению

Об авторах

- -

Список литературы

  1. Мухин Н.А., Балкаров И.М. Подагрическая почка. В: Тареева И.Е. (ред.) Нефрология. Руководство для врачей. М.: Медицина, 2000, 422 - 427
  2. Domrongkitchaiporn S., Sritara P., Kitiyakara C. et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J. Am. Soc. Nephrol. 2005; 16: 791 - 799
  3. Тареев Е.М. Гипертоническая болезнь. М.: Медгиз, 1948
  4. Dolder M.A., Oliver M.F. Myocardial infarction in young men. Study of risk factors in nine countries. Br. Heart J. 1975; 37(5): 493-503
  5. Culleton B.F., Larson M.G., Kannel W.B., Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann. Intern. Med. 1999; 131(1): 7-13
  6. Yang Q., Guo C.Y., Cupples LA. et al. Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study. Metabolism. 2005; 54(11): 1435-1441
  7. Gordon T., Kannel W.B. Drinking and its relation to smoking, BP, blood lipids, and uric acid. The Framingham study. Arch. Intern. Med. 1983; 143(7): 1366-1374
  8. Sharpe C.R. A case-control study of alcohol consumption and drinking behaviour in patients with acute gout. Can. Med. Assoc. J. 1984; 131(6): 563-567
  9. Miao Z., Li C., Chen Y. et al. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J. Rheumatol. 2008; 35(9): 1859-1864
  10. Gaffo A.L., Roseman J.M., Jacobs D.R. Jr. et al. Serum urate and its relationship with alcoholic beverage intake in men and women: findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. Ann. Rheum. Dis. 2010 Jun 4. [Epub ahead of print]
  11. Choi H.K., Atkinson K., Karlson E.W. et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004; 363(9417): 1277-1281
  12. Bhole V., de Vera M., Rahman M.M. et al. Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. Arthritis Rheum. 2010; 62(4): 1069-1076
  13. Reyes A.J. Cardiovascular drugs and serum uric acid. Cardiovasc. Drugs Ther. 2003; 17(5-6): 397-414
  14. Gurwitz J.H., Kalish S.C., Bohn R.L. et al. Thiazide diuretics and the initiation of anti-gout therapy. J. Clin. Epidemiol. 1997; 50(8): 953-959
  15. Bomback A.S., Derebail V.K., Shoham D.A. et al. Sugar-sweetened soda consumption, hyperuricemia, and kidney disease. Kidney Int. 2010; 77(7): 609-616
  16. Borges R.L., Hirota A.H., Quinto B.M. et al. Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy. J. Clin. Hypertens. (Greenwich). 2009; 11(5): 253-259
  17. Choi J.W., Ford E.S., Gao X., Choi H.K. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis. Rheum. 2008; 59(1): 109-116
  18. Choi H.K., Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. B.M.J. 2008; 336(7639): 309-312
  19. Hak A.E., Choi H.K. Menopause, postmenopausal hormone use and serum uric acid levels in US Women - the Third National Health and Nutrition Examination Survey. Arthritis Res. Ther. 2008; 10(5): R116
  20. Indraratna P.L., Williams K.M., Graham G.G., Day R.O. Hyperuricemia, cardiovascular disease, and the metabolic syndrome. J. Rheumatol. 2009; 36(12): 2842-2843
  21. Carnethon M.R., Fortmann S.P., Palaniappan L. et al. Risk factors for progression to incident hyperinsulinemia: the Atherosclrosis Risk in the Communities Study, 1987 - 1998. Am. J. Epidemiol. 2003; 158: 1058 - 1067
  22. Choi H.K., Ford E.S. Prevalence of metabolic syndrome in individuals with hyperuricemia. Am. J. Med. 2007; 120: 442-447
  23. Донсков А.С., Балкаров И.М., Голубь Г.В. и др. Клиническое значение индекса массы тела и индекса талия/бедро у пациентов с артериальной гипертонией: связь с уровнем мочевой кислоты в крови. Клин. мед. 2002; 80(1): 31-34
  24. Villegas R., Xiang Y.B., Cai Q. et al. Prevalence and determinants of hyperuricemia in middle-aged, urban Chinese men. Metab. Syndr. Relat. Disord. 2010; 8(3): 263-270
  25. Sui X., Church T.S., Meriwether RA. et al. Uric acid and the development of metabolic syndrome in women and men. Metabolism. 2008; 57(6): 845-852
  26. Puig J.G., Martínez M.A., Mora M. et al. Serum urate, metabolic syndrome, and cardiovascular risk factors. A population-based study. Nucleosides Nucleotides Nucleic. Acids.; 27(6): 620-623
  27. Li N.F., Wang H.M., Yang J. et al. Serum uric acid is associated with metabolic risk factors for cardiovascular disease in the Uygur population. Appl. Physiol. Nutr. Metab. 2009; 34(6): 1032-1039
  28. Choi H.K., Ford E.S. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels - the Third National Health and Nutrition Examination Survey. Rheumatology (Oxford). 2008; 47(5): 713-717
  29. Rocić B., Vucić-Lovrencić M., Poje N. et al. Uric acid may inhibit glucose induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells. Bioorg. Med. Chem. Lett. 2005; 15(4): 1181-1184
  30. Chien K.L., Chen M.F., Hsu H.C. et al. Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin. Chem. 2008; 54(2): 310-316
  31. Rizos C.V., Liberopoulos E.N., Mikhailidis D.P., Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert. Opin. Pharmacother. 2008; 9(7): 1087-1108
  32. Vitart V., Rudan I., Hayward C. et al. SLC2A9 is a newly identified urate transopter influencing serum urate concentrations, urate excretiona and gout. Nat. Genet. 2008; 40: 437 - 442
  33. Doring A., Gieger C., Mehta D. et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat. Genet. 2008; 40: 430 - 436
  34. Graessler J., Graessler A., Unger S. еt al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum. 2006; 54(1): 292-300
  35. Li C., Han L., Levin A.M. et al. Multiple single nucleotide polymorphisms in the human urate transporter 1 (hURAT1) gene are associated with hyperuricaemia in Han Chinese. J. Med. Genet. 2010; 47(3): 204-210
  36. Jang W.C., Nam Y.H., Park S.M. et al. T6092C polymorphism of SLC22A12 gene is associated with serum uric acid concentrations in Korean male subjects. Clin. Chim. Acta. 2008; 398(1-2): 140-144
  37. Chaves F.J., Corella D., Blesa D. et al. Xanthine oxidoreductase polymorphisms: influence in blood pressure and oxidative stress levels. Pharmacogenet. Genomics 2007; 17: 589-596
  38. Watanabe S., Kang D.H., Feng L. et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002; 40(3): 355-360
  39. Feig D.I., Kang D.-H., Johnson R.J. Uric acid and cardiovascular risk. N. Engl. J. Med. 2008; 359(17): 1811-1821
  40. Sundstrom J., Sullivan L., D'Astino R.B. et al. Relations of serum uric acid to longitudinal blood pressure traching and hypertension incidence. Hypertension 2005; 45: 28-33
  41. Krishnan E., Kwoch C.K., Schumaher H.R., Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49: 298-303
  42. Lu Z.S., Lu Z.H., Lu H. et al. Association between hyperuricemia and hypertension in a Chinese population at a high risk of hypertension. Blood Press. 2009; 18(5): 268-272
  43. Ouppatham S., Bancha S., Choovichian P. The relationship of hyperuricemia and blood pressure in the Thai army population. J. Postgrad. Med. 2008; 54(4): 259-262
  44. Lee J.E., Kim Y.G., Choi Y.H. et al. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension 2006; 47: 962 - 967
  45. Alper A.B. Jr., Chen W., Yau L. et al. Childhood uric acid predicts adult blood pressure. The Bogalusa Heart Study. Hypertension 2005; 45: 34-38
  46. Jones D.P., Richey P.A., Alpert B.S., Li R. Serum uric acid and ambulatory blood pressure in children with primary hypertension. Pediatr. Res. 2008; 64(5): 556-561
  47. Мухин Н.А., Балкаров И.М., Шоничев Д.Г., Лебедева М.В. Формирование артериальной гипертонии при уратном тубуло-интерстициальном нефрите. Тер. арх. 1999; 71(6): 23-27
  48. Viazzi F., Leoncini G., Ratto E. et al. Mild hyperuricemia and subclinical renal damage in untreated primary hypertension. Am. J. Hypertens. 2007; 20(12): 1276-1282
  49. Domrongkitchaiporn S., Sritara P., Kitiyakara C. et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J. Am. Soc. Nephrol. 2005; 16: 791 - 799
  50. Iseki K., Oshiro S., Tozawa M. et al. Sighnificance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens. Res. 2001; 24: 691- 697
  51. Shan Y., Zhang Q., Liu Z. et al. Prevalence and risk factors associated with chronic kidney disease in adults over 40 years: a population study from Central China. Nephrology (Carlton). 2010; 15(3): 354-361
  52. Satirapoj B., Supasyndh O., Chaiprasert A. et al. Relationship between serum uric acid levels with chronic kidney disease in a Southeast Asian population. Nephrology (Carlton). 2010; 15(2): 253-258
  53. Chang H.Y., Tung C.W., Lee P.H. et al. Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am. J. Med. Sci. 2010; 339(6): 509-515
  54. Ingsathit A., Thakkinstian A., Chaiprasert A. et al.; Thai-SEEK Group. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol. Dial. Transplant. 2010; 25(5): 1567-1575
  55. Tsai J.C., Chen S.C., Hwang S.J. et al. Prevalence and risk factors for CKD in spouses and relatives of hemodialysis patients. Am. J. Kidney Dis. 2010; 55(5): 856-866
  56. Mazzali M., Hughes J., Kim Y.G. et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001; 38(5): 1101-1106
  57. Kang D.H., Nakagawa T., Feng L. et al. A role for uric acid in the progression of renal disease. J. Am. Soc. Nephrol. 2002; 13(12): 2888-2897
  58. Sánchez-Lozada L.G., Tapia E., Santamaría J. et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005; 67(1): 237-247
  59. Kanellis J., Kang D.H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin. Nephrol. 2005; 25(1): 39-42
  60. Щербак А.В., Балкаров И.М., Козловская Л.В. и др. Фибринолитическая активность мочи как показатель поражения почек при нарушении обмена мочевой кислоты. Тер. арх. 2001; 73(6): 34-37
  61. Albertoni G., Maquigussa E., Pessoa E. et al. Soluble uric acid increases intracellular calcium through an angiotensin II-dependent mechanism in immortalized human mesangial cells. Exp. Biol. Med. (Maywood). 2010; 235(7): 825-832
  62. Kosugi T., Nakayama T., Heinig M. et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am. J. Physiol. Renal Physiol. 2009; 297(2): F481-F488
  63. Haririan A., Nogueira J.M., Zandi-Nejad K. et al. The independent association between serum uric acid and graft outcomes after kidney transplantation. Transplantation. 2010; 89(5): 573-579
  64. Siu Y.P., Leung K.T., Tong M.K., Kwan T.H. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am. J. Kidney Dis. 2006; 47(1): 51-59
  65. Navaneethan S.D., Beddhu S. Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease. Nephrol. Dial. Transplant. 2009; 24(4): 1260-1266
  66. Suliman M.E., Johnson R.J., García-López E. et al. J-shaped mortality relationship for uric acid in CKD. Am. J. Kidney Dis. 2006; 48(5): 761-771
  67. Wen C.P., David Cheng T.Y., Chan H.T. et al. Is high serum uric acid a risk marker or a target for treatment? examination of its independent effect in a large cohort with low cardiovascular risk. Am. J. Kidney Dis. 2010 Jun 2. [Epub ahead of print]
  68. Fang J., Alderman M.H. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. J.A.M.A. 2000; 283(18): 2404-2410
  69. Krishnan E., Svendsen K., Neaton J.D. et al.; MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. Arch. Intern. Med. 2008; 168(10): 1104-1110
  70. Baker J.F., Schumacher H.R., Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology. 2007; 58(4): 450-457
  71. Langlois M., De Bacquer D., Duprez D. et al. Serum uric acid in hypertensive patients with and without peripheral arterial disease. Atherosclerosis. 2003; 168(1): 163-168
  72. Chen J.H., Chuang S.Y., Chen H.J. et al. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009; 61(2): 225-232
  73. Kim S.Y., Guevara J.P., Kim K.M. et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009; 61(7): 885-892
  74. Kim S.Y., Guevara J.P., Kim K.M. et al. Hyperuricemia and coronary heart disease: a systematic review and meta analysis. Arthritis Care Res. (Hoboken). 2010; 62(2): 170-180
  75. Okura T., Higaki J., Kurata M. et al.; Japanese Coronary Artery Disease Study Investigators. Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. Circ. J. 2009; 73(5): 885-891
  76. Choi H.K., Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007; 116(8): 894-900
  77. Dunkelgrun M., Welten G.M., Goei D. et al. Association between serum uric acid and perioperative and late cardiovascular outcome in patients with suspected or definite coronary artery disease undergoing elective vascular surgery. Am. J. Cardiol. 2008; 102(7): 797-801
  78. Iwashima Y., Horio T., Kamide K. et al. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension. 2006; 47(2): 195-202
  79. Kuo C.F., Yu K.H., Luo S.F. et al. Role of uric acid in the link between arterial stiffness and cardiac hypertrophy: a cross-sectional study. Rheumatology (Oxford). 2010; 49(6): 1189-1196
  80. Tavil Y., Kaya M.G., Oktar S.O. et al. Uric acid level and its association with carotid intima-media thickness in patients with hypertension. Atherosclerosis. 2008; 197(1): 159-163
  81. Kawamoto R., Tomita H., Oka Y. et al. Association between uric acid and carotid atherosclerosis in elderly persons. Intern. Med. 2005; 44(8): 787-793
  82. Neogi T., Ellison R.C., Hunt S. et al. Serum uric acid is associated with carotid plaques: the National Heart, Lung, and Blood Institute Family Heart Study. J. Rheumatol. 2009; 36(2): 378-384
  83. Pacifico L., Cantisani V., Anania C. et al. Serum uric acid and its association with metabolic syndrome and carotid atherosclerosis in obese children. Eur. J. Endocrinol. 2009; 160(1): 45-52
  84. Li Y., Xu C., Yu C. et al. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J. Hepatol. 2009; 50(5): 1029-1034
  85. Yamamoto Y., Matsubara K., Igawa G. et al. Status of uric acid management in hypertensive subjects. Hypertens. Res. 2007; 30(6): 549-554
  86. Goicoechea M., Vinuesa S.G., Verdalles U. et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin. J. Am. Soc. Nephrol. 2010 Jun 10. [Epub ahead of print]
  87. Kanbay M., Ozkara A., Selcoki Y. et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int. Urol. Nephrol. 2007; 39(4): 1227-1233
  88. Hoieggen A., Alderman M.H., Kjeldsen S.E. et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004; 65: 1041-1049
  89. Мухин Н.А., Балкаров И.М., Моисеев С.В. и др. Урикозурическое действие лозартана. Клин. фармакол. тер. 2003; 5: 59-63
  90. Athyros V.G., Elisaf M., Papageorgiou A.A. et al.; GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am. J. Kidney Dis. 2004; 43(4): 589-599
  91. Ogata N., Fujimori S., Oka Y., Kaneko K. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids. 2010; 29(4-6): 321-324
  92. Berbari A. The role of uric acid in hypertension, cardiovascular events and chronic kidney disease. ESH Scientific Newsletter. 2010; 11:#49

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах